Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:

Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_3720_Библиотеки_им_академика_М_И_Перельмана

.pdf
Скачиваний:
0
Добавлен:
31.08.2026
Размер:
30 Мб
Скачать
List of Contributors xxiii
https://t.me/med1917
Neil P. Lewis, MD, PhD, FACC
Medical Director Heart Failure MCS, Transplantation Department Cardiology McGuire Veterans Affairs Medical Center Richmond, VA, United States; Professor of Medicine Virginia Commonwealth University School of Medicine Richmond, VA, United States
Jurgen Ligthart
Erasmus University Rotterdam Rotterdam, The Netherlands
Michael Lishner, MD
Professor of Medicine Sackler Faculty of Medicine Tel Aviv University Head, Research Institute Head, Department of Medicine A Meir Medical Center Kfar Saba, Israel
Alejandro E. Macias, MS
Division of Cardiothoracic Surgery and
the Miami Transplant Institute
University of Miami Miller School of Medicine and
Jackson Memorial Hospital
Michael Magarakis, MD
Division of Cardiothoracic Surgery and
the Miami Transplant Institute
University of Miami Miller School of Medicine and
Jackson Memorial Hospital
Miami, Florida, United State s
Ahmed N. Mahmoud, MD
Department of Medicine Division of Cardiovascular Medicine University of Florida Gainesville, FL, United States
Dhruv Mahtta, MD, MBA
Department of Medicine University of Florida Gainesville, FL, United States
Anit Mankad, MD
Assistant Professor of Medicine, Virginia Commonwealth
University Health System Richmond, VA, United States; Transplant Cardiologist, Hunter Holmes McGuire VA
Medical Center Richmond, VA, United States
Claudia A. Martinez, MD, FACC
Division of Cardiology University of Miami Medical Center Associate Professor Clinical Medicine University of Miami Miller School of Medicine Miami, FL, United States
Rodrigo Mendirichaga, MD
Section of Cardiovascular Medicine Boston Medical Center, Boston University School of
Medicine
Boston, MA, United States
Elizabeth Michalets, PharmD, BCPS, FCCP
Mission Health System and the University of North
Carolina Eshelman School of Pharmacy Manager, Pharmacy Education and Research Professor of Clinical Education Asheville, NC, United States
Benjamin Michalove, PharmD, CPP
PGY1 Pharmacy Residency Program Director Clinical Pharmacy Specialist Charles George Veterans Affairs Medical Center Asheville, NC, United States
Subhashis Mitra, MD
Assistant Professor Department of Medicine Michigan State University East Lansing, MI, United States
Srikanth Nagalla, MBBS, MS
Associate Professor of Medicine Program Director, Hematology/Oncology Fellowship Division of Hematology/Oncology UT Southwestern Medical Center Dallas, TX, United State s
Massimo Napodano, MD, PhD
Interventional Cardiology Department of Cardiac Thoracic and Vascular Sciences University of Padova Padova, Italy
Peter OKane, BSc, MBBS, MD, FRCP
Consultant Interventional Cardiologist Dorset Heart Centre Royal Bournemouth Hospital Bournemouth, Dorset, United Kingdom
xxiv List of Contributors
https://t.me/med1917
Takayuki Onishi, MD, FACC
Interventional Cardiologist Department of Cardiology Hiratsuka Kyosai Hospital Hiratsuka, Kanagawa, Japan
Yuko Onishi, MD, FACC
Director, Department of Cardiology Hiratsuka Kyosai Hospital Hiratsuka, Kanagawa, Japan
Amir Orlev, MD
Barts Health NHS Trust London, United Kingdom
Ada M. Palmisano, PhD
Department of Applied Mathematics and Statistics Colorado School of Mines Golden, Colorado, United States
Gabriella Passacquale, MD, PhD
Clinical Lecturer Clinical Pharmacology Cardiovascular Division Kings College London London, United Kingdom
Brian T. Peek, PharmD
Chief of Pharmacy Coordinator Research and Development Charles George Veterans Affairs Medical Center Asheville, NC, United States; Clinical Associate Professor of Pharmacy Practice Wingate University School of Pharmacy Wingate, NC, United States
Divaka Perera, MD, FRCP
Consultant Cardiologist Department of Cardiology Guys & St. ThomasHospital London, United Kingdom
Krishnaraj S. Rathod, MRCP
Department of Cardiology Barts Health NHS Trust London, United Kingdom; NIHR Cardiovascular Biomedical Research Cen tre Barts Heart Centre London, United Kingdom
Evelyn Regar, MD, PhD
University Hospital Zurich Zürich, Switzerland
Claire Ren, MD
Erasmus University Rotterdam Rotterdam, The Netherlands British Heart Foundation Clinical Research Fellow Kings College London London, UK
Uri Rosenschein, MD, MBA, FACC, FESC, FSCAI
Chief, Department of Car diology Bnai Zion Medical Center Professor of Medicine Technion Medical School Haifa, Israel
Matthew J. Ryan, BSc (Hons), MBChB, MRCP
British Heart Foundation Clinical
Research Fellow, Kings College London
London, United Kingdom
Negar Salehi, MD
Michigan State University East Lansing, MI, United States
Tomas A. Salerno, MD, FACC, FSTS, FACS
Division of Cardiothoracic Surgery and The Miami Transplant Institute Professor of Surgery University of Miami Miller School of Medicine and
Jackson Memorial Hospital
Miami, FL, United States
Andres M. Pineda, MD, FACC
Cardiac Catheterization Laboratory University of Florida College of Medicine e Jacksonville Division of Cardiology Jacksonville, FL, United States
Sunil V. Rao, MD, FACC, FACP, FSCAI
Professor of Medicine Duke University Medical Center Section Chief, Cardiology Durham Veterans Affairs Medical Center NC, United States
Satinder K. Sandhu, MD, FACC, FACP
Clinical Professor, Pediatrics Director, Pediatric Cardiac Cath Lab Director, Adult Congenital Heart Disease University of Miami, Miller School of Medicine & Jackson
Memorial Hospital
Miami, FL, United States
List of Contributors xxv
https://t.me/med1917
Ian J. Sarembock, MB, ChB, MD, FACC, FSCAI
Medical Director, Valve & Structural Heart
Disease Division
Harold C. Schott Foundation
Endowed Chair in Structural Heart
The Christ Hospital Health Network & Lindner Center for
Research and Education
Cincinnati, OH, United States
Edward J. Sawey, MD
Fellow, Division of Cardiology Virginia Commonwealth University Richmond, VA, United States; Hunter Holmes McGuire VA Medical Center Richmond, VA, United States
Amit Segev, MD, FACC, FSCAI, FESC
Professor of Medicine Sackler School of Medicine Tel Aviv University, Israel Head, Cardiovascular Institution Leviev Heart Center Sheba Medical Center Tel Hashomer, Israel
Nicolas W. Shammas, MD, MS, EJD, FACC, FSCAI
Adjunct Clinical Associate Professor Internal Medicine University of Iowa Hospitals and Clinics Davenport, IA, United States; Research Director and Founder Midwest Cardiovascular Research Foundation Davenport, IA, United States
Yu-Min Shen, MD
Associate Professor of Medicine Division of Hematology/Oncology UT Southwestern Medical Center Dallas, TX, United States
Arthur Shiyovich, MD, FACC
Department of Cardiology Institute of Interventional Cardiology Rabin Medical Center Petach Tikva, Israel; Sackler Faculty of Medicine Tel Aviv University Tel Aviv, Israel
Satya S. Shreenivas, MD, FACC
Division of Interventional Cardiology Division of Valve and Structural Heart The Christ Hospital Heart and Vascular Center and
The Lindner Center for Research and Education
Cincinnati, OH, United States
James Smith, MD, FACC, FSCAI
Division of Cardiology Wake Forest Baptist Health Winston-Salem, NC, United States
Elliot J. Smith, MD, FRCP
Department of Cardiology Barts Health NHS Trust London, United Kingdom; NIHR Cardiovascular Biomedical Research Centre Barts Heart Centre London, United Kingdom
Emily Stumpf, DO
Division of Pediatric Cardiology Jackson Memorial Hospital Miami, Florida, United States
Allyne Topaz, MD
Surgical Resident, PG-4, Department of Surgery Brooklyn Medical Center Brooklyn, NY, United States
Imre Ungi, MD
Division of Invasive Car diology Second Department of Internal Medicine and
Cardiology Center University of Szeged Szeged, Hungary
Avraham Unterman, MD, MBA
Pulmonologist, Pulmonary Division
Rabin Medical Center Beilinson Campus, Petah Tikva, Israel; Sackler Faculty of Medicine Tel Aviv University Tel Aviv, Israel
Gemma Vilahur, PhD, FESC
Senior Researcher Cardiovascular Program ICCC Institut de Recerca Hospital de la Santa Creu i Sant Pau IIB-Sant Pau, Barcelona; CIBERCV-ISCIII, Madrid, Spain
Renu Virmani, MD, FACC, FACP
Professor of Pathology Georgetown University - School of Medicine Washington D.C. Medical Director/President CVPath Institute, Inc. Gaithersburg, United States
xxvi List of Contributors
https://t.me/med1917
Thomas E. Watts, MD, FACC
Division of Cardiovascular Disease University of Alabama at Birmingham Birmingham, AL, United States
Emily E. Wood, PharmD
Clinical Pharmacy Specialist Charles George Veterans Affairs Medical Center Asheville, NC, United States; Adjunct Faculty Member Mercer University College of Pharmacy Atlanta, GA, United States
Arwa Younis, MD, FACC
Department of Cardiology The Leviev Heart Center Sheba Medical Center and Sackler School of Medicine Tel Aviv University Ramat Gan, Israel
Richard L. Zampolin, MD
Division of Radiology Monteore Medical Center Albert Einstein School of Medicine Bronx, NY, United States
Foreword
https://t.me/med1917
It gives me great pleasure to contribute the foreword for the rst edition of this splendid book by Dr. On Topaz, Professor of Medicine, Duke University School of Medicine, and Chief, Division of Cardiology, Charles George Veterans Affairs Medical Center, Asheville, North Carolina, entitled Cardiovascular Thrombus: From Pathology and Clinical Presentation to Imaging, Pharmacotherapy, and Interventions, by the publisher Elsevier.
There is no doubt about the importance of thrombosis in medicine today. It serves in clinical medicine as an important growth area of research and clinical activities, as well as a major topic involving a multidisciplinary group approach that includes internal medicine, hematology, radiolo gy, gen e ral ca r diolo gy, interventional cardiology, and cardiac surgery. Although the role of throm bo si s leading to both chronic car dio vasc ul ar disease and acute life­threatening complications has been recognized for many years, clinical developments in recent years have helped to illuminate the pathophysiological changes affecting both thrombosis and thrombolysis, as well as our ability to diagnose and modify these processes.
This book provides a comprehensive, contemporary source of research and clinical practice related to the current aspects of the diagnosis and management of cardiovascular thrombosis. It is well known that the hemostatic system serves to maintain a delicate balance between the processes of coagulation and anticoagulation, platelet activation and inhibition, and activation and inhibition of brinolysis to ensure vascular patency. Abnormalities in these processes can precipitate hemorrhage or arterial and venous thrombosis. Acute thrombotic e vents characterize common clinical manifestations of cardiovascular disease, including acute coronary syndrome, myocardial infarction, and ischemic stroke. Antithrombotic interventions, such as aspirin, platelet receptor inhibitors, P2Y12 inhibitors, and thrombolytic agents, underpin the management of cardiovascular disease, highlighting the critical role of thrombosis in cardiovascular morbidity and mortality.
This book has been published at a most opportune time. It is among the rst books yet written on this important subject, and I believe it is among the more ambitious and best productions on this topic. It is designed to help physicians in all specialties as they apply recent information about thrombosis, the coagulation system, and cardiovascular diseases. The editor and the contributing authors are highly respected world leaders in this eld and their background, personal contributions, and deep knowledge of the subject complement one a nother remarkably. At the same time, the book is intensely practical, thus bringing the unique knowledge and insights of the contributing authors and the editor to bear on the interpretation of the experimental and clinical observations in this rapidly expanding eld.
Cardiovascular thrombus is of paramount importance for researchers and practicing physicians, yet it remains among the most challenging diagnosti c and clinical scenarios. This important refer en ce book bridg es the gap between research, up-to-da te clinical information, and the technological facets of thrombus formation, di ag nos is, and management in c ar diov ascu la r medicine. The book includes complete coverage of pathology, clinical presentation s, diagnosis, pharmacotherapy , interventions, and future trends set in a comprehensive, up-to-date format. Furthermore, this book also considers the potential future ap plica ti on s of various technologies in furt heri ng our understanding of the mechanisms contributing to formation of cardiovascular thrombus and to thrombus resolution, which may ultimately lead to the identication of additional therapeutic pathways that could be targeted for development of new antithrombotic therapies.
I would like to congratulate Dr. On Topaz and his excellent group of distinguished contributing authors who accomplished in each chapter of this book the indispensable concepts required to approach critical diagnostic and therapeutic needs in clinical cardiovascular medicine. The introduction of newer techniques for the diagnosis and treatment of thrombotic cardiovascular disease has changed considerably the diagnostic and therapeutic scenarios. The recent advances in the study of thrombosis have altered permanently the management of patients with cardiovascular disease as well as healthy persons who are at risk for development of cardiovascular thrombotic diseases.
xxvii
xxviii Foreword
https://t.me/med1917
Finally, I wish that all readers of this book enjoy and use it as a benecial tool as much as I myself did. I believe that this textbook will prove invaluable to all researchers and investigators of thromboembolic disorders, as well as to noninvasive cardiologists, interventional cardiologists and radiologists, vascular and cardiovascular surgeons, internists, hematologists, vascular medicine specialists, pharmacists, and medical students, all of whom wish to consider choices and make informed clinical decisions when dealing with cardiovascular thrombus and thromboembolic problems in their daily practice.
Igor F. Palacios, MD, FACC, FACP, FSCAI
Director of Interventional Cardiology
Massachusetts General Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Preface
https://t.me/med1917
The extraordinary work of art on the books cover illustrates dramatically the ominous threat thrombus imposes on the heart and great vessels and, by implication, the entire cardiovascular system and lif e. This painting on canvas by the artists Scott Meskill and Shannon Donnelly reects their visual interpretation of thrombus and thrombosis while they were in attendance at an Emergency Medicine conference. We chose to exhibit this painting as the gate opener to an all-inclusive book, covering the full spectrum of cardiovascular thrombus.
My personal odyssey toward all things thrombus was launched during fellowships training in cardiovascular pathology, cardiology, and interventional cardiology. This education brought to light the prevalence and catastrophic effects of cardiovascular thrombus as observed from the unique perspective of these intertwining disciplines. In the pa­thology suite, we studied hearts, vessels, organs, and accompanying thrombi in patients who had died from complications attributed to cardiovascular thrombi, gaining a nal view on the inicted damage. Thus, clinically, I serve as a long­standing observer to the ubiquitous and rich clinical presentations of cardiovascular thrombi, while participating in the development of dedicated management strategies and related technologies.
As clinicians, we constantlywitness and dealwith the tremendousinjury thrombi causepatients. Intriguingly, thrombusis an essential component of hemostasis, yet its formation frequently serves as a harbinger of vascular complication or as a blatant testimonial to an already existing cardiovascular damage. Thrombusis omnipresent in the arterial and venous circulation, inside cardiac chambers, adhering to valves, lodging in the great vessels, and embolizingthroughthe vasculature to many organs.The extraordinary pathology and complex morphologic features of different types of thrombi and related physical and rheolytic properties are of signicant interest to many. Indeed, thrombi are a study in biologic contradictions: some rmly attach to structures and vessels while others oat freely. Thrombi vary in age and often exhibit fresh layers interspersed with or superimposed over oldlayers.A thrombus size can be anywherefrom microscopicto largedat times evenreachinga monstrous length and shape. Thrombi are built of unique constituents and carry select signature receptors that excrete procoagulants and vasoactive reactants, making them strongly susceptible to accumulation. The brittle and unstable nature of thrombi means unpredictable clinical outcomes, thrombi are commonly resistant to extraction yet prone to embolization even if treated.
While writing the chapter The Thrombus-Containing Lesionfor consecutive editions of the Textbook of Interven- tional Cardiology, edited by Topol and Teirstein, Elsevier, I developed a growing interest in the potential of a new book aimed at comprehensive coverage of contemporary research, clinical, diagnostic, manag ement, and therapeutic aspects of cardiovascular thrombus. The publisher Elsevier readily agreed to embrace this quest, and I am grateful for the privilege of editing this book. Accordingly, special thanks to Ms. Stacy Masucci, Senior Acquisitions Editor, Biomedical Research and Reference, at Elsevier. Personal appreciation is expressed to Mr. Samuel Young, the books project manager. Ms. Arya Dowis, 4th year medical student from the Edward Via College of Osteopathic Medicine, provided thoughtful academic contributions to the book project which are highly appreciated. All along this project, here at the Charles George Veterans Affairs Medical Center, the gifted Matt Holtz, BS, RCIS, provided outstanding technical support, excellent electronic media preparation, and insightful advice.
Upon the publication of this book, I wish to express a deep gratitude to the distinguished contributing authors, comprising scientists, researchers, and clinicians who responded afrmatively to my invitation, generously contributing their time and talent. Consequen tly, the scientic data as published in this book represent an array of contemporary views on multiple topics. The contributing authors and I trust that the readership, including students, scientists, and clinicians alike, from the vast elds of medicine, will benet from the teaching points and profound expertise and stands to nd this book a comprehensive and interesting resource.
Finally, our sincere wish is that this book will cultivate further research and lead to the development of new therapies. May many patients around the world benet from the knowledge gained by the readers.
On Topaz, MD
Asheville, NC, USA
xxix
https://t.me/med1917
2 Cardiovascular Thrombus
https://t.me/med1917
TABLE 1.1 Distribution of Culprit Plaques by Sex and Age in Sudden Coronary Death
No Acute Thrombi (Stable Severe
Acute Thrombi (n [ 236)
Calcified
Subpopulation
Men ages <50 years 82 (48%) 34 (20%) 3 (2%) 16 (9%) 36 (21%) 171
Men ages 50 years 59 (31%) 14 (7%) 6 (3%) 46 (24%) 63 (34%) 188
All men 141 (39%) 48 (13%) 9 (3%) 62 (17%) 99 (28%) 359
Women ages <50 years 3 (6%) 16 (36%) 0 (0%) 4 (9%) 21 (48%) 44
Women ages 50 years 10 (26%) 6 (15%) 3 (8%) 8 (21%) 12 (31%) 39
All women 13 (16%) 22 (27%) 3 (4%) 12 (14%) 33 (40%) 83
Total population 154 (35%) 70 (16%) 12 (3%) 74 (17%) 132 (30%) 442
Histological definition of CTO was defined as lumen area occupied by proteoglycan and /or collagen with or without neovascularization and chronic inflammation. Organized thrombi with healed myocardial infarction ¼ 62/74 (84%). No thrombi (stable plaque) with healed myocardial infarction ¼ 71/132 (54%). CAD, coronary artery disease; CTO, chronic total occlusion. Reprinted from Yahagi K, et al. Sex differences in coronary artery disease: pathological observations. Atherosclerosis 2015;239(1):260e7 © with permission from Elsevier.
Nodule
Organized Thrombi (CTO) No Thrombi
CAD) (n [ 206)
TotalRupture Erosion
Plaque Rupture
Plaque rupture is dened by the presence of a disrupted thin brous cap with overlying thrombus and an underlying necrotic core. The underlying necrotic core in plaque rupture usually occupies >30% of the total plaque area [8e10] (Fig. 1.1A). The thin brous cap is made up of type I collagen with very few smooth muscle cells interspersed, but is inltrated by varying numbers of macrophages and T lymphocytes. The mean brous cap thickness at the rupture site is 23 19 mm, and 95% of the brous caps are <64 mm [5]. The disrupted brous cap allows contact of owing blood with the highly thrombogenic necrotic core. This blood allows large numbers of platelets to be activated and aggregate at the rupture site forming a white thrombus (Figs. 1.2 and 1.3). The thrombus may or may not lead to a complete obstruction of the coronary lumen. If there is obstruction and a side branch is present proximal to the obstruction site, the thrombus propagates to the side branch and consists of layers of brin (lines of Zahn) separated by red blood cells, classied as a red thrombus. Eventually, if the thrombus is not removed or crushed by angioplasty or thrombolysis, it will organize by inltration of inammatory cells, especially macrophages, releasing growth factors that attract endothelial cells and smooth muscle cells, which proliferate and deposit extracellular matrix consisting of proteoglycans and collagen, leading to or­ganization of the thrombus and chronic total occlusion of the coronary artery.
Ruptured plaques (PRs) are believed to be preceded by thin-cap broatheromas (TCFAs) , also called vulnerable plaques, which are likely precursor lesions of PRs, except that the cap is intact and less than 65 mm, the necrotic core is smaller, and the lesions are less calcied. We have reported on the radiographic appearance of calcium in ruptures, erosions, and TCFAs. Calcication is greatest in ruptures, followed by TCFAs, and least in erosions [11]. With regard to location of disruption of the brous cap in PRs, human autopsy studies have shown that rupture occurs not only at shoulder regions but also at the midportion of the brous cap [12]. In addition, rupture at the thinnest, midportion of the brous cap was associated with exercise [12]. Also, emotional stress has been reported to precipitate cardiac events [13]. Select proteases secreted by macrophages possibly weaken the brous cap, and high shear and tensile stress all may be involved in triggering rupture [14,15]. In addition, microcalcication (>5 mm) originating from dying macrophages or smooth muscle cells has also been hypothesized to possibly trigger rupture, possibly due to increased stress that leads to interfacial debonding [16,17].
In 1997, Burke et al. reported an association between serum lipid prole (total cholesterol, high-density lipoprotein (HDL) cholesterol, ratio of total cholesterol to HDL), smoking (serum thiocyanate, a surrogate marker for smoking), and plaque rupture in 113 men who died suddenly. Among them, 96.5% had one or more risk factors regardless of etiology of coronary thrombus, with smoking being a predictor of acute thrombosis [18]. Plaque rupture was associated with high total cholesterol, low HDL cholesterol, and elevated ratio of total to HDL cholesterol. In addition, patients who had high levels of total cholesterol had a greater number of TCFAs. Diabetes was a predictor of stable plaque, as well as total and distal
Histopathology of Cardiovascular Thrombus Chapter | 1 3
https://t.me/med1917
(A) (B) (C) (D)
Rupture
Th
Underlying PIT
Th
Erosion
Underlying FA
Th
Th
NC
Th
Calcified nodule
Th
Smooth muscle cells
Macrophage foam cells
Extracellular lipid
Cholesterol clefts
Necrotic core
Calcified plaque
Nodular
++
NC
Ca
Collagen
Hemorrhage
Thrombus
Healed thrombus
Angiogenesis
Fibrin
FIGURE 1.1 Human coronary lesion morphologies categorized as lesions with acute thrombi.Histological and schematic images are shown for
(A) plaque rupture, (B) plaque erosion with underlying pathological intimal thickening (PIT), (C) plaque erosion with underlying broatheroma (FA), and (D) calcied nodule. Arrowheads indicate brous cap. NC, necrotic core; Th, thrombus. Histological images in (A), (B), and (D) reprinted from Falk E,
Nakano M, Bentzon JF, Finn AV, Virmani R. Update on acute coronary syndromes: the pathologistsview. Eur Heart J 2013;34(10):719e28 by permission of Oxford University Press and the European Society of Cardiology. (C) Reprinted from Otsuka F, et al. Clinical classication of plaque morphology in coronary disease. Nat Rev Cardiol 2014;11:379e89 with permission from Elsevier.
Thrombus Propagation in Plaque Rupture
(A)
1mm
(B)
Platelet-rich thrombus
LD
LAD
Proximal fibrin-rich propagated thrombus
(D)
FIGURE 1.2 Thrombus propagation in plaque rupture. (A) Composition of a longitudinal section of the LAD coronary artery with plaque rupture; the
rupture site is marked by the arrowhead (Movat pentachrome, original magnication 20). (B) The same longitudinal section as in (A) stained with Carstairsmethod for the detection of brin (dark red) and platelets (blue-gray). The proximal thrombus consists predominantly of brin with red cells interspersed, while the distal portion of the rupture site is platelet rich. (C) Platelets were further conrmed using antibody directed against glycoprotein IIIa. (D) Proximal propagated portion of the thrombus showing mostly brin and red cells; mild layered reactivity is seen for platelets. LD, left diagonal branch; LAD, left anterior descending. Reproduced with permission from Virmani R, Narula J, Leon MB, Willerson JT, editors. The vulnerable
atherosclerotic plaque. Plaque Rupture. MA, USA: Blackwell Futura; 2007 [Chapter 3]. p. 53. Figure 3.15.
(C)
Carstairs
Platelets
Proximal
Propagated
Thrombus
,
Platelet
Fibrin